Police looking for band of eight robbers; Outten gets bail despite serious gun charges Recommended for you Turks & Caicos and United States team up for ‘Don’t Pack a Pest’ program Related Items:Clyde Scottie Glinton, customs department, supreme court, theft Facebook Twitter Google+LinkedInPinterestWhatsAppProvidenciales, 23 Feb 2016 – Police today reveal that Clyde Scottie Glinton did not fight the charge of stealing from the Customs Department between November 2011 and January 2012.Glinton entered a guilty plea at Supreme Court in Provo.Over the three months, Scottie Glinton, once a senior Customs Officer at the Provo International Airport, took money which should have gone from the PIA to Customs Central Unit and pocketed it.Glinton was the officer in charge and the amount was $19,273.42.Glinton was on Monday (Feb 22)fined $25,000 and sentenced to three years in jail; the jail time is conditional so he will not serve the time but could if he finds himself in trouble with the law again.Clyde ‘Scottie’ Glinton has 90 days to pay the fine, else be imprisoned for 12 months.Generally, this is a fortunate break for the public officer who was arrested in connection to the theft in September 2013. Facebook Twitter Google+LinkedInPinterestWhatsApp 7 BAIC workers arrested for Theft
WILMINGTON, MA — Below is an important announcement from the Wilmington Police Department:Chief Joseph Desmond reports that the Wilmington Police Department is investigating shots fired in the area of Salem Street and Ring Avenue.On May 13, 2019, Wilmington Police responded to the area of Ring Avenue and Salem Street at approximately 12:45am, for the report of shots fired. Officers secured the area and commenced an investigation into the complaint. The scene was quickly determined to be safe and Officers conducted their investigation and processed the scene.At this time, Police located 5 shell casing from a firearm in the area of Salem Street and Ring Avenue.No one was injured in this incident.The Wilmington Police Department is actively investigating the incident and anyone with additional information is encouraged to contact the Wilmington Police Department at 978-658-5071.Like Wilmington Apple on Facebook. Follow Wilmington Apple on Twitter. Follow Wilmington Apple on Instagram. Subscribe to Wilmington Apple’s daily email newsletter HERE. Got a comment, question, photo, press release, or news tip? Email email@example.com.Share this:TwitterFacebookLike this:Like Loading… RelatedPOLICE LOG for July 2: Wilmington Man Arrested On Warrant; Family Causes Scene At Silver Lake?In “Police Log”POLICE LOG for August 19: Fist Fight At Planet Fitness; Hawk Stuck Inside Building; Gas Line StruckIn “Police Log”POLICE LOG for June 19: Fire Dept. Delayed By Train When Responding To Crash; Duck Flew Into House; Turtle Stuck In PoolIn “Police Log”
Kolkata: The Chief Metropolitan Magistrate (CMM) has summoned BJP national president Amit Shah to appear before the Court on September 28 in connection with an alleged defamation case filed by Abhishek Banerjee, Trinamool Congress MP and president of the All India Trinamool Youth Congress.On August 11, Amit Shah had made certain defamatory statements against Abhishek at the BJP’s Yuva Swabhiman Samavesh rally on Mayo Road. Shah had said that the funds released by the Centre worth Rs 3.59 lakh crore to Bengal ended up with Abhishek, who is Chief Minister Mamata Banerjee’s nephew, and syndicates. Also Read – Rain batters Kolkata, cripples normal life”The residents of the villages in Bengal, has the money reached your village? Prime Minister Modi had sent it. Where did Rs 3,59,000 crore go? This has been gifted to the nephew and the syndicate,” Shah had said in the rally. “Narada, Saradha, Rose Valley, syndicate’s corruption, nephew’s corruption… a series of corruption have been carried out under Mamataji,” Shah had said. These statements were widely published and circulated all over the country in various newspapers and on social media. Also Read – Speeding Jaguar crashes into Mercedes car in Kolkata, 2 pedestrians killedOn August 13, Banerjee’s advocate had served a notice to Amit Shah, calling upon the accused to retract such virulent and mala fide defamatory statements and to issue an unconditional apology to the complainant. No response was received by Abhishek Banerjee or his advocate. Later, a complaint case was filed on August 28 before the CMM by the complainant under Section 500 of the Indian Penal Code (Punishment for defamation). Cognizance was taken by the CMM on August 28. On Wednesday, the application was fixed for examination of the complainant and the witnesses, when Abhishek Banerjee as well as the witnesses, Swarup Biswas and Soumya Bakshi appeared and made their statements, on oath, before the CMM.
in the photo: the “Suspension” bridge model[photo by Ivan Pintar]in the photo: the exhibition opening.[photo by Ivan Pintar]in the photo: the model of 3D Jersey in the atrium.[photo by Ivan Pintar]in the photo: The 3D Jersey model viewed from above.[photo by Annette Del Zoppo]There was a lot of press about this exhibition, some of the notable articles were:“Structure to House a City” by Paul Richard, WASHINGTON POST, February 17. 1970.‘Cities in Buildings’ Exhibits Lure, Rebel at the Corcoran” by M.M. Flatley, THE EVENING STAR, Washington D.C., February 21. 1970.“Fantasy Metropolis” by Wolf Von Eckardt, THE WASHINTON POST, February 21. 1970.“Will Tomorrow be lived in a Soleri City” by Diana McLellan, THE EVENING STAR, Washington D.C., February 26. 1970. Part of this article is about Paolo Soleri’s wife Colly “The Woman Behind Soleri”.“Architect of Tomorrow – A radical vision of the future in a spectacular exhibition at Washinton’s Corcoran Gallery”, ART GALLERY MAGAZINE, March 1970.“There’s no Place to go but up” by Paul Richard, THE SUNDAY STAR BULLETIN, March 1. 1970.“The Arcologist” by Douglas Davis, NEWSWEEK, March 2. 1970.“The Fantastic City” CHRONICLE SUNDAY PUNCH, March 8. 1970.“Architect Views a Crowded Spaceship” by John V. Conti, THE WALL STREET JOURNAL, March 11. 1970.“Prophet in the Desert” by Ada Louise Huxtable, THE NEW YORK TIMES, March 15. 1970: “The Architectural Vision of Paolo Soleri” is an important and beautiful show.”“Mr. Soleri and His Better Plumbing” by John Pastier, THE NATIONAL OBSERVER, March 23. 1070“Soleri and Guimard are subjects of two major exhibits – Arcology stirs up a storm” ARCHITECTURAL RECORD, April 1970.“Soleri’s Solution” FORUM, April 1970.“Soleri’s Cities on Display” PROGRESSIVE ARCHITECTURE, April 1970.“Architeture” by Frederick Gutheim, NATION, New York, April 13. 1970.“A Dream to cure the urban nightmare – Sea Cities and vertical land cities”, INDUSTRY WEEK, April 20. 1970.“Visions of the City” by Louise Huxtable, THE STARS AND STRIPES, April 21. 1970.“Paolo Soleri: The Fine Art of Living” by Allen Brown Gardner, FINE ARTS, April 27. 1970.“Paolo Soleri & His Arcologies” by Tom Miller, ROLLING STONE, April 30. 1970“The Arcology of Paolo Soleri” by Sibyl Moholy-Nagy, ARCHITECTURAL FORUM, May 1970“Soleri’s urban landscape” INDUSTRIAL DESIGN, May 1970This report continues on Friday, July 8. 2016. July 6, 2016We continue our report about the Paolo Soleri exhibition at the Corcoran Gallery in Washington, D.C. in 1970 with photos of the exhibition opening.The exhibition “The Architectural Vision of Paolo Soleri” opened on February 21. 1970. in the photo: at the opening in front of “Mesa City” plan, a montage of three scroll drawings, each 48 inches wide, making a display of 34 feet wide and 12 feet tall.[photo by Ivan Pintar]in the photo: at the opening – the model of the original “Arcosanti” design.There was an invitation mounted at the Arcosanti model, something along the lines of: “This summer we are starting to build Arcosanti in the Arizona desert, come join us”.And people came and they are still coming. [photos by Ivan Pintar]
Newly elected state Rep. Diana Farrington, R-Utica, is joined by her husband, Jeff, as she is administered the ceremonial oath of office by Michigan Supreme Court Chief Justice Stephen Markman. The 99th Michigan Legislature began session today following the swearing-in ceremonies. People can contact Rep. Farrington by calling 517-373-7768, by email at DianaFarrington@house.mi.gov or by mail at N-794 House Office Building, P.O. Box 30014, Lansing MI 48909.##### Categories: Diana Farrington News,Diana Farrington Photos,News 11Jan Rep. Farrington administered ceremonial oath of office
If your dog is outside make sure that it always has an adequate supply of fresh clean water and a place to shelter from the sun. If possible, bring outside dogs inside on hot days. Dog walkers should be aware than on a hot day of 25ºC with little wind and low humidity the paving and tarmac can reach a scorching 52ºC. Dog walkers should consider the “5 second rule” – this is a simple test where you place the back of your hand on the pavement. If you cannot hold it for five seconds then it’s too hot to walk your dog. Dogs paws are just as sensitive as human feet and susceptible to getting painfully burned even on days that don’t appear overly hot. Older and obese dogs, as well as dogs with medical problems should be kept inside if possible. Snub-nosed such as Bulldogs, Pugs, Boston Terriers, Lhasa Apsos, and Shih Tzus can also be susceptible to hot weather problems and should be watched for signs of overheating. The best time for walking or playtime with your dog is in the cool of the early morning or evening, but never after a meal or when the weather is very hot and humid as dogs can dehydrate very quickly. ShareTweet Cars can be death traps for dogs, even with the windows open. A car can go from comfortable to oven-like in minutes, so never leave your dog alone in a car. And don’t think that a cloudy day or parking in the shade reduces the risks. The sun moves during the day and clouds can actually magnify the heat. If you are taking your dog along in the car for a long trip, always carry a container of cool water for him. Bringing your dog to the beach is fine, as long as you can ensure he will have shade when he needs it and plenty of clean, fresh water. If your dog likes to swim in the sea, be sure to wash him off with fresh water as soon as possible as salt water can be rough on the coat and skin. Summer also brings dangers in the form of insecticides, weed sprays, and snail baits, to name a few, so watch out for these hazards in gardens and on your walks. Tips for keeping your dog cool in the summer heat was last modified: July 2nd, 2019 by John2John2 Tags: DERRY City and Strabane District Council is advising dog owners to look after their pets in the summer heat.A spokesperson said: “Summers here, so don’t forget that dogs suffer from the same problems as ourselves in hot weather – dehydration, overheating, and even sunburn. “If you keep a few things in mind and take action early, you and your dog can have a great summer! cool waterdehydrationDerry and Strabane CouncilTips for keeping your dog cool in the summer heat
Third, Celsion’s LTSL technology promotes an accelerated release of the drug when and where it will be most effective. That allows for direct targeting of organ-specific tumors. Celsion’s LTSL technology has shown that it’s capable of delivering drugs to the tumor site at concentrations up to 30 times greater than those achievable with chemotherapeutics alone, and three to five times greater than those of more traditional liposome-encapsulated drug-delivery systems. The company’s first drug under development is ThermoDox, which uses its breakthrough LTSL technology to encapsulate doxorubicin, a widely used chemotherapeutic agent that is already approved to treat a wide range of cancers. Currently, ThermoDox is undergoing a pivotal Phase III global clinical trial – denoted the “HEAT study” – for the treatment of primary liver cancer (hepatocellular carcinoma, or HCC), in combination with radiofrequency ablation (RFA). RFA uses high-frequency radio waves to generate a high temperature that is applied with a probe placed directly in the tumor, which by itself kills tumor cells in the immediate vicinity of the probe. Cells on the outer margins of larger tumors may survive, however, because temperatures in the surrounding area are not high enough to destroy them. But the temperatures are high enough to activate Celsion’s LTSL technology. Thus, the heat from the radio-frequency device thermally activates the liposomes in ThermoDox in and around the periphery of the tumor, releasing the encapsulated doxorubicin to kill remaining viable cancer cells throughout the region, all the way to the tumor margin. ThermoDox is also undergoing a Phase I/II clinical trial for the treatment of recurrent chest wall (RCW) breast cancer (known as the “DIGNITY study”), and a Phase II clinical trial for the treatment of colorectal liver metastases (the “ABLATE study”). But most of the drug’s (and hence the company’s) value is tied up in the HEAT study. The HEAT trial is a pivotal 700-patient global Phase III study being conducted at 79 clinical sites under a special protocol assessment (SPA) agreement with the FDA. The FDA has designated the HEAT study as a fast-track development program, which provides for expedited regulatory review; and it has granted orphan-drug status to ThermoDox for the treatment of HCC, providing seven years of market exclusivity following FDA approval. Furthermore, other major regulatory agencies, including the European Medicines Agency (EMA) and China’s equivalent, have all agreed to use the results of the HEAT study as an acceptable basis to approve ThermoDox. The primary endpoint for the HEAT study is progression-free survival – living longer with no cancer growth. There’s a secondary confirmatory endpoint of overall survival, too. Both the oncological and investing community are eagerly awaiting the results, which are due any day now. So then, why are we on the sidelines now, right when the big news is due to hit? That all goes back to why Celsion was such a good investment to begin with, and what it can tell us about finding other big wins in the technology stock market. A Winner in the Making When we’re looking for a strong pick in the biotechnology, pharmaceuticals, and medical devices fields – once we have established the quality of the technology itself and ensured it will likely work as expected – there is a simple set of tests we apply to ensure that we’ve found a stock that can deliver significant, near-term upside. The most critical of these are: The technology must provide a distinct competitive advantage over the current standard of care and be superior to any competitors’ effort that will come to market before or shortly after our subject’s does. In other words, it must improve outcomes, by improving patients’ length or quality of life (i.e., a cure for a disease, or a maintenance medication with fewer side effects), or lower costs while maintaining quality of care (i.e., a generic drug). A therapy that does both is all the better. There must a clear path to market in the short term, or another catalyst to propel the stock upward. An investment in a great technology does not always make for a great investment. You have to consider the quality of the management team and structure of the company, including its ability to pay the bills and get to market without defaulting or diluting you out of your positions. And of course, time. The biggest and most frequent mistake investors make in technology is assuming that it is smooth and short sailing from concept to market. Reality is much harsher than that, and in biotechnology and pharmaceuticals in particular – with a tough regulatory gamut to run – the timeline to take a new technology to market can be anywhere from a decade to thirty, forty, or even fifty years. Liposomes are a perfect example of that. Twenty years ago, I probably could have told you a story about a technology that was very similar to what was laid out above. It would be compelling and enticing to investors of all stripes – a breakthrough technology with the promise to revolutionize cancer care by making chemo less toxic and more effective at the same time. Yet had you invested in that promise alone, chances are you’d be completely wiped out by now, or maybe – just maybe – still waiting for a return. That is why we invest in proof, not promises. So, how does Celsion stack up against our four main proof points? Time to market: When we first recommended Celsion, it was in Phase III pivotal trials. This is the last major stage of human testing usually required before a company can submit an FDA New Drug Application and apply to market the product. The process of bringing a drug to market, even once a specific compound has been identified and proven to work in vitro (in the lab), is perilous. Many things can go wrong along the way. If you look at investing in a company whose drugs are just entering Phase I clinical trials, for instance, it is still unclear if the therapy is effective in vivo (in the human body). This is a critical stumbling block for many companies, whose promising compounds immediately prove less effective or more dangerous than testing suggested. Even if Phase I goes well, it can take up to a decade and sometimes longer to get from there to market with a drug. And then, even Phase II trials often leave treatments five or more years from market – though there are exceptions in cases where a therapy is proven very effective or a disease has so few treatment options available. But shortcuts are rare, and investors have to consider the time and expense (which leads to fundraising and ultimately dilutes your return) of getting from A to Z. In this regard, Celsion made a uniquely great investment. When we first recommended the company, it was in the midst of a pivotal Phase III trial and looked to be about a year or so away from its first commercialization. (Though, speaking to the length of these trials, this one had been started back in 2008.) With many of the most high-profile companies in the industry – those working on vogue treatment areas and conditions, like hepatitis C treatments of late – when they get this close to market, the large banks bid up stocks to high levels, content to squeeze just a few percentage points out at the end. They have to be conservative, since they’re investing large amounts of other people’s money. However, biotechnology is such a fragmented space with far more companies than Wall Street can possibly cover in depth, that coming across a gem like Celsion late in the game with a potentially big win is not as uncommon as you’d think. The “efficient market” hypothesis fails to account for the fact that no one can know everything, including every stock. And Celsion had gone all but unnoticed for some time. Payer acceptability: Celsion has the benefit of developing a 2.0-style product, an improvement over something that already exists. RFA is already in relatively widespread use and has proven effective enough that most every insurance and benefits provider will cover it. Even the early generations of LTSL, while not quite as safe or effective as desired, were enough of a benefit to gather pretty solid support from payers. Celsion, through its clinical trial process, has proven its unique blend is safer, better tolerated by patients, and much more effective than its predecessors. Thus, payer support at a reasonable price is a pretty sure bet. Market size: When we originally recommended Celsion, we stated that the company was sitting on a multibillion-dollar opportunity. And we stand by that statement. However, just because something is eventually worth that amount does not mean it’s bankable today as a short-term investment. So we try to keep our analysis narrowly focused on what can be directly counted on and measured. In Celsion’s case, that’s the Phase III treatment, Thermodox, and the one area in which it is being studied: primary liver cancer (HCC). Even just in this narrow band, however, we see the market opportunity for Celsion as in excess of $1 billion. HCC is one of the most deadly forms of cancer. It currently ranks as the fifth most-common solid tumor cancer, and it’s quickly moving up. With the fastest rate of growth among all cancer types, HCC projects to be the most prevalent form of cancer by 2020. The incidence of primary liver cancer is nearly 30,000 cases per year in the US, and approximately 40,000 cases per year in Europe. But the situation worldwide is far worse, with HCC growing at approximately 750,000 cases per year, due to the high prevalence of hepatitis B and C in developing countries. If caught early, the standard first-line treatment for primary liver cancer is surgical resection of the tumor. Early-stage liver cancer generally has few symptoms, however, so when the disease is finally detected, the tumor is usually too large for surgery. Thus, at least 80% of patients are ineligible for surgery or transplantation by the time they are diagnosed. And there are few nonsurgical therapeutic treatment options available, as radiation and chemotherapy are largely ineffective. RFA has emerged as the standard of care for non-resectable liver tumors, but it has limitations. The treatment becomes less effective for larger tumors, as local recurrence rates after RFA directly correlate to the size of the tumor. (As noted earlier, RFA often fails at the margins.) ThermoDox promises the ability to reduce the recurrence rate in HCC patients when used in combination with RFA. If it proves itself in Phase III, there’s no doubt the drug will be broadly adopted throughout the world once it is approved. A quick look at the numbers: According to the most recent data from the National Cancer Institute, the incidence rates of HCC per 100,000 people in the three major markets are 4 in the US, 5 in Europe, and approximately 27 in China. Based on these incidence rates, the total addressable market in these three regions (which we will conservatively assume to be the total addressable worldwide population for the time being) is approximately 400,000 (12,000 in the US, 40,000 in Europe, and 351,000 in China). Assuming that 50% of HCC patients are eligible for nonsurgical invasive therapy such as RFA, approximately 200,000 patients worldwide would be eligible for ThermoDox. Further assuming an annual cost of treatment for ThermoDox of $20,000 in the US, $15,000 in Europe, and $5,000 in China, in line with similar treatments of the same variety, we estimate that the market potential of ThermoDox could be up to $1.3 billion. Not to mention the countless thousands of lives saved. (And that’s before the rest of the developing world comes online.) Of course, this is an estimate of ThermoDox’s potential assuming 100% market penetration – something that simply never happens. While we expect ThermoDox in combination with RFA to become the standard of care for primary liver cancer, a more reasonable expectation for maximum market penetration after a six-year ramp-up to peak sales (from an expected approval in 2013) is probably 40%. Improving outcomes or lowering costs: This is exactly what the Phase III trial was intended to prove: efficacy beyond a shadow of a doubt. Given preliminary data and earlier trial results, it was already a pretty sure thing, so in our model, we assumed about a 70% chance of success (to be on the conservative side, as always – it’s better to be right by a mile than to miss by an inch). Once we incorporate that probability of success into our model, we come to a probability-weighted peak sales figure in 2019 of approximately $365,000,000 annually. The average-price-to-sales ratio among the big players in biotech these days is about 5. If we apply a sales multiple of 3 (i.e., just 60% of the average) to Celsion’s probability-weighted peak sales for ThermoDox in 2019, we come up with a value for the company of nearly $1.1 billion, which would equate to about $33 per share if it did not issue any new stock between now and then – that’s more than 17 times where the stock was trading when we recommended a buy. And remember, these numbers are only for ThermoDox under the HCC indication. Our Move to the Sidelines With final data from the current Phase III pivotal trial due expected to come in within the next few weeks, Celsion’s stock has ballooned in value from the $2 range to $7.50 or so in the past few weeks. Now, that’s a far cry from the $33 price we mentioned above, but remember, that’s a target for 2019. And it doesn’t allow for a whole range of things that could go wrong. Chief among those concerns is that the Phase III data come in more poorly than expected. Even just a small variance in efficacy or a simple question about safety can knock a few hundred million dollars off those sales figures. Or it can push trials back a year or two, delaying returns and sending short-term-minded investors, like those who have recently bid up CLSN shares, retreating to the hills for the time being. Further downfield there is sure to be competition as well, and of course we may get those miraculous chemo-free treatments mentioned up front. In short, we don’t have a crystal ball and can’t tell you what the world will look like in 2019. If you believe yours is clear, ask yourself if you thought touchscreen phones and tablets would outsell traditional computers by 3 to 1 globally in 2012. If not, you might want to give the crystal a polish. To be clear, the value of Celsion in the near term hinges on a binary event – the results of the ongoing HEAT trial. We are of the opinion that CLSN represents one of the best opportunities we’ve come across since we started this letter, and that the probability of a successful trial is high. Nevertheless, there is substantial down side if the trial is unsuccessful. And it could take years to recover, if ever, on news of a delay from any concerns raised. We’d already advised subscribers to take a free ride early on in our coverage of the stock, taking all of the original investment risk away. However, even with that protection, the short-term potential is still more heavily weighted to the down side. Thus, we booked our profits and stepped to the sidelines on this one. Celsion continues to be a model, even at today’s prices, for a great biotech investment with significant upside potential. But we’re content to wait for the market to hand us another, similar opportunity. The pages of Casey Extraordinary Technology are filled with investments just like Celsion – up-and-coming technology companies the market has yet to discover. Subscribe today and save 25% off the regular price, as always backed by our unconditional money-back guarantee. Bits & Bytes More 3D-Printer Magic (Gizmag) Last week, we noted some of the cool things people are doing with 3D printers. But it’s hard to keep up. The tech is blasting ahead so fast that this week we couldn’t resist adding another. Researchers at the University of Warwick, already known for its cutting-edge tech research, have created a cheap, plastic composite that can be used even with low-end 3D printers to produce custom-made electronic devices. The potential here is staggering. Tablets – Hotter than We Thought (Computerworld) Global market-research company IDC has revised its estimate for sales of tablets for 2012 upward by 4.5%, to 122.3 million units. Apple is expected to lose market share to surging Android-based devices. Whose Internet Is It? (GamePolitics) Well, the US Congress appears to think it’s the people’s. Other countries disagree, and have been trying to wrest control of the ‘Net from our hands for a while now. Many want the UN in charge. But this week, the House unanimously passed a Senate resolution calling on the US government to officially oppose any transfer of Net control to the UN. We’d guess this battle is far from over, though. Tattoo You? (Gizmag) Next time you see a runner with a smiley-face tattoo on his or her arm, you might be looking at a sophisticated metabolic sensor, designed to detect stress due to exertion. Of course, we aren’t always in a smiley frame of mind, are we? So if we could just cross one of these things with a mood ring… We are not ones for bragging about our accomplishments. Whether you believe in such mystical forces as karma or not, it’s generally a good rule that those who take too much credit for their successes are soon rewarded with a streak of the opposite, just to keep them humble. However, it is just as important to take stock in your achievements as it is your failures, if you are going to learn and grow as an investor (or in any pursuit). As such, this week I want to introduce you to the story of a company that we recommended to our investment advisory subscribers back in April 2012. It’s since gone on to gain significantly. The stock rose 297% from our initial recommendation to the day the “sell” call was made. What’s important about this small company is why it made our investment list to begin with, and what its characteristics can tell us about successful speculation in the arena of up-and-coming technology companies. Sincerely, Alex Daley Chief Technology Investment Strategist Casey Research Anatomy of Great Technology Investment By Alex Daley, Chief Technology Investment Strategist Traditional cancer treatment options are little more than a crude mix of “slash, burn, and poison” – that is surgery, radiation, and chemotherapy. There are radical new treatments in labs and trials all over the world that promise to throw out this trifecta; no other disease has received more of the research interest and funding that have defined modern biotechnology over the past three decades. I’m not going to tell you about any of those here. Sure, many of them will be wildly successful and make many investors fabulously wealthy over the next few decades. But most will fail. And those that don’t will take a long time to turn a profit for investors. Yet, there is one small company whose unique twist on cancer treatment is proving to be a major upgrade. We profiled this company in a recent edition of Casey Extraordinary Technology, and it turned in a gain of over 167% for subscribers in just six months’ time. It may yet make billions more still for investors. You see, in recent years chemotherapy has become the core treatment for most cancerous malignancies. And while these toxic cocktails of chemicals have proven effective at destroying cancerous cells, they also have one problem. A big one. Chemo, being essentially a poison, doesn’t just attack cancerous cells – it attacks a broad range of healthy cells too. As a result, the treatment can sometimes be as harmful as the cancer itself in the short run. The side effects are awful, and its use can quickly erode patients’ health. Some have even described chemo as a “cure that’s worse than the disease.” This sad state of affairs for the world’s second most-prevalent chronic disease is why the cancer-research arena has been exploding over the past few years with the goal of developing more targeted, less-toxic therapies – in other words, to do a better job killing cancer cells while leaving healthy cells alone. That’s exactly what Lawrenceville, New Jersey-based Celsion Corp. (CLSN) has the technology to do. And chances are the company is on to one of the biggest cancer-treatment breakthroughs in decades. How It Works Our story starts with liposomes. These nanosized artificial vesicles are made from the same material as our cell membranes – natural phospholipids, i.e., a version of the chemicals that make up everything from fat to earwax, and cholesterol. Not long after their discovery in the 1960s, scientists began experimenting with liposomes as a means of encapsulating drugs, especially cancer drugs. Why? Something called the “enhanced permeability and retention” (EPR) effect. This is a property of certain sizes of molecules – for example, liposomes, nanoparticles, and macromolecular drugs – which tend to accumulate in tumor tissue much more than they do in normal tissues. It’s a useful feature for a cancer drug. Thus, they offer a potential way to combat the two biggest drawbacks of traditional chemotherapeutics: systemic toxicity and low bioavailability at the tumor site. In other words, the drugs now employed are themselves are toxic to normal cells, and they tend to get largely used up before they even reach the tumor site. Early attempts to encapsulate drugs inside liposomes did an okay job of dealing with the toxicity issue, but bioavailability at the tumor site was still limited. Our immune system saw to that. Just like virtually anything else artificial we put into our bodies, traditional liposomes were seen as invaders. Thus, they were rapidly cleared by the mononuclear phagocyte system, the part of the immune system centered around the spleen (yes, we do use it) that destroys viruses, fungi, and other foreign invaders. However, a breakthrough arrived when scientists came up with a new way to sneak these artificial compounds into the body undetected by our defenses. The process gave us what are call “PEGylated” liposomes, with a covalent attachment of polyethylene glycol polymer chains. The effect of attaching these little plastic chains to the end of the liposome was to create a “stealth” liposome-encapsulated drug that was hardly noticed by the system. Problem solved, right? Well, not exactly. A lot of hard work went into getting drugs into liposomes to reduce toxicity, then a bunch more into stopping our immune system from kicking in. But there was still yet another problem. The drug-release rates of these stealth liposomes were generally so low that tumor cells barely got a dose. Scientist had made them so stealthy that they even skated right by cancer cells, usually failing to kill off the tumors. After decades of experimenting with liposome-encapsulated cancer drugs, scientists still had not been able to safely deliver therapeutic concentrations of the chemotherapy drugs to all tumor cells. They had to devise a way to induce drug release when and where it would be more effective. The next big idea came in more recent years, as scientists devised temperature-sensitive liposomes. Heat them and they pop, releasing the drugs just when you need them to. From stealth to non-stealth in a matter of seconds, and right on target. Fortunately, they were able to make it work, but unfortunately, not at temperatures that didn’t essentially cook patients from the inside – sort of defeating the purpose of keeping the chemo at bay to reduce collateral damage. They failed to perform at tolerable levels of heat or time. Fifteen minutes of baking and still only 40% or so of the drug was released, and it took temperatures up to 112° Fahrenheit. It might not sound like much, but it was enough to be intensely painful and damaging as well. That’s where Celsion came in. It’s designed and developed a novel form of these temperature-sensitive chemo sacks – the first of their kind to work effectively and safely – otherwise known as a lysolipid thermally sensitive liposome (LTSL). Celsion’s liposomes are engineered to release their contents between 39-42° C, or 102.2-107.6° F (thus, another translation of LTSL has become “low-temperature sensitive liposome”). And they release the contents at an extremely fast rate, to boot. A Better Way to Use Chemo These unique properties of Celsion’s LTSL technology make it vastly superior to previous liposome technology for a number of reasons. For starters, the temperature range is much more tolerable to patients and won’t injure normal tissue. Payers should be easily convinced to cover the new therapy at profitable rates. In the modern world of health care, failure of a treatment to garner coverage from government medical programs like Medicare and the UK Health Service, and private insurance companies (which generally cooperate closely to decide how to classify and whether to cover a treatment) is usually a game-ender. Payers have a responsibility not just to patients but to their shareholders or taxpayers to stay financially solvent. This means that if a therapy does not provide a compelling cost/benefit ratio, then it won’t be covered. For instance, if you release a new painkiller that is only as effective as Tylenol and costs $1,000 per dose, you’re obviously not going to see support. Second, the temperature range takes advantage of the natural effect mild hyperthermia has on tumor vasculature. Numerous studies have shown that temperatures between 39-43° C increase blood flow and vascular permeability (or leakiness) of a tumor, which is ideal for drug delivery since the cancer-killing chemicals have easy access to all areas of the tumor. These effects are not seen at temperatures below this threshold, and temperatures above it tend to result in hemorrhage, which may reduce or cease blood flow, hampering drug delivery. It’s the Goldilocks Effect: The in-between range is perfect. The market must be measurable and addressable. There must be some way to say specifically how many patients would benefit from a therapy, and to ensure that those patients have providers caring for them that would make efficient distribution of the therapy possible. For instance, a successful treatment for Parkinson’s disease might be applicable to hundreds of thousands of patients, with little competition from other treatments, whereas a treatment for Von Hippel-Lindau (VHL) might only reach hundreds. If the goal is to recover years of research investment and profit above and beyond that, then market size matters, as do current and future competitors that might limit your reach within a treatment area.
We’re beginning to approach oversold territory and, as you probably already know, how soon we get to those lows will depend on how quickly the powers-that-be take the remaining slices. A re-read of Ted’s quote above would be useful at this point. And as I type this paragraph, the London open is just under ten minutes away. Gold, platinum and palladium prices are unchanged—and silver is up a nickel. Gold’s net volume is very light at just under 11,500 contracts—virtually all of it of the HFT variety—and silver’s net volume is around 4,200 contracts, with decent roll-overs out of July already. And after rallying about 20 basis points in the early going in Hong Kong trading on their Friday morning, the dollar index is back to unchanged. Without doubt, all eyes will be on the job numbers this morning in New York—and what trading ‘action’ will accompany their release. Of course the job numbers should make no difference to the gold price at all, but a long history shows that JPMorgan et al use that as an excuse on many occasions to drive the precious metal prices into the dirt—and I’ll be amazed if that doesn’t happen this morning. Today we get the Commitment of Traders Report for positions held at the close of COMEX trading on Tuesday—and I doubt if we’ll see much, if any, improvement in the Commercial net short positions in either gold or silver, as the reporting week was pretty flat from a price perspective. All the price action that mattered most didn’t start until the day after the cut-off—and it’s a very safe bet that it was no accident that it happened this way, as “da boyz” have used this trick for at least a decade when they want to hide their tracks for as long as possible. We also get the companion Bank Participation Report as well. This is data that’s extracted directly from the COT Report—and shows what the world’s banks have been up to during the month that was and, as I always say at this juncture, they’re usually up to quite a bit. I’ll have all that data in my Saturday column. And as I send the Friday edition of today’s column out the door at 5:25 a.m. EDT, I see that gold began to develop a slight negative bias starting at 2 p.m. Hong Kong time on their Friday afternoon. Ditto for silver. Gold is down a couple of bucks, but silver is still up a nickel. Platinum and palladium are trading flat. Gold’s net volume is now a bit over 22,000 contracts—and silver’s net volume is pretty decent as well at 6,500 contracts, but there’s been no increase in roll-over activity from over two hours ago. The dollar index was slowly heading south, but has recovered a bit in the last half hour—and is currently down only 3 basis points. As I said above, all eyes will be on the 8:30 a.m. EDT jobs report—and if you’re feeling a bit like that poor chap in the last cartoon posted above, I’ll certainly understand—as I feel that way myself at the moment. Enjoy your weekend, or what’s left of it if you live west of the International Date Line—and I’ll see you here tomorrow. Here’s the 5-minute gold tick chart courtesy of Brad Robertson. As you can tell by the volume spikes, “da boyz” stuck it to the Managed Money traders real good once again during the COMEX trading session. Midnight Wednesday is the vertical gray line—and you have to add two hours for EDT—and the ‘click to enlarge’ feature is a must. The silver chart was similar to gold’s, right up until 3:30 p.m. in the New York Access market. At that point a willing seller stepped in and ensured that silver closed on its absolute low tick of the day. The high and low ticks were reported by the CME Group as $16.50 and $16.065 in the July contract. Silver finished the Thursday session at $16.075 spot, down 40 cents on the day. Gross volume was very decent, as was net volume—46,000 contracts. Avrupa and Antofagasta intersect copper-rich VMS in Pyrite Belt, Portugal • First Greenfields discovery of massive sulfide mineralization in 20 years in the Iberian Pyrite Belt • 10.85 meters of massive and semi-massive/stockwork sulfide mineralization grading 1.81% Cu, 2.57% Pb, 4.38% Zn, 0.13% Sn, and 75.27 ppm Ag • Including 7.95 meters @ 2.21% Cu, 3.05% Pb, 4.82% Zn, 0.15% Sn, 89.8 ppm Ag • Followed by 2.90 meters @ 0.71% Cu, 1.27% Pb, 3.17% Zn, 0.092% Sn, 35.4 ppm Ag • Avrupa and Antofagasta sign an amended Joint Venture Agreement Please visit our website to learn more about the company and current exploration program. Platinum prices were a mini version of the gold price chart—and palladium was a mini version of the platinum chart. Platinum closed on Thursday at $1,098 spot, down three bucks, finally cracking the $1,100 spot price to the downside. Palladium also closed 3 dollars lower at $753 spot. Here are the charts. The CME Daily Delivery Report for Day 5 of the June delivery month showed that zero gold and 9 silver contracts were posted for delivery within the COMEX-approved depositories on Monday. Nothing to see here. The CME Preliminary Report for the Thursday trading session showed that gold open interest for June dropped another 282 contracts, leaving 1,262 still open. June o.i. in silver was up 7 contracts to 40. There was no reported change in GLD, but another deposit was made in SLV. This time it was 1,433,379 troy ounces. So far this week, there has been a bit over 2.5 million ounces deposited in SLV. Since the price action indicates that silver should be flowing out of that ETF, the deposits must have been used to cover an existing short position. We’ll have to wait until about June 23 when the next short position report comes out of the folks over at shortsqueeze.com in order to get a hint of what might be going on. Since yesterday was Thursday, Joshua Gibbons, the Guru of the SLV Bar List, updated his website with the goings-on over at the iShares.com Internet site at the close of trading on Wednesday—and this is what he had to report. “Analysis of the 03 June 2015 bar list, and comparison to the previous week’s list: 1,138,121.2 troy were added (all to Brinks London), 893,539.6 oz were removed (all from Brinks London), and 113 bars had serial number changes.” “The bars removed were from: Solar Applied Materials (0.3M oz, Krasnoyarsk (0.2M oz), and 10 others. The bars added were from: Krasnoyarsk (0.2M oz), Prioksky (0.1M oz), and 13 others. “As of the time that the bar list was produced, it was overallocated 384.9 oz. All daily changes are reflected on the bar list.” Over at Switzerland’s Zürcher Kantonalbank for the week ending May 29—they reported tiny declines in both their gold and silver ETFs. Their gold ETF shed 1,804 troy ounces—and their silver ETF dropped only 7,123 troy ounces. After four straight day of sales, it should come as no surprise that there was no report from the U.S. Mint yesterday. Over at the COMEX-approved depositories on Wednesday, there was 50,092 troy ounces of gold transferred from Canada’s Scotiabank to HSBC USA. Other than that, there was no activity worth mentioning, but the link to what there was, is here. It was another huge in/out day in silver, as 411,788 troy ounces were received—all at JPMorgan’s vault—and 1,012,058 troy ounces were shipped out. All of the ‘out’ movement was from Canada’s Scotiabank, including the 411,788 troy ounces that JPMorgan received. The link to that action is here—and it’s worth a quick look. There wasn’t a lot of activity at the COMEX-approved gold kilobar depositories in Hong Kong on their Wednesday, as only 775 kilobars were reported received—and another 475 were shipped out. All of the action was at Brink’s, Inc. as usual. The link to that activity is here. I have a fair number of stories for you today—and I’ll happily leave the final edit up to you. Since we penetrated for the first time to the downside the key 50-day moving average in silver on Wednesday, I suppose the official price take-down cycle is now in effect. Gold, you’ll remember, had penetrated its 50-day moving average a week or so ago, so the market structure there is more advanced than it is in silver. Therefore, in silver, it’s more a question of how many contracts the commercials can induce the managed money traders to sell than it is how low prices must fall. It’s more about contracts sold than prices, although successive lower prices (salami slicing) are necessary to effect the full contract count outcome. In other words, it’s not necessary that we drop dramatically in price, just enough—and in the manner necessary to accomplish whatever complete managed money selling results this go around. Of course, please dismiss any suggestion that I (or anyone else) know for sure the direction of prices in the short term. This is about probabilities based upon the same thing that those probabilities have always been based on – past and prospective COT patterns. And even though those probabilities suggest lower silver prices ahead, any such decline should prove minor compared to the eventual much higher prices that the actual fundamentals and facts point to. While I hope my COT analysis is beneficial, please understand it is not my intent to handicap silver prices in the short term, although many others do seem so engaged. Instead, my intent is to use my analysis of the COT market structure to show just how screwed up is the price discovery process on the COMEX and, after 30 years, it is encouraging to see that at least one silver miner may feel the same. In the unfortunate circumstance that the probabilities once again prove correct and we do witness further declines in the price of silver, perhaps that might aid in convincing other silver producers to step up to the plate and write to the CFTC. Trying to come up with rational explanations for why silver and gold prices behave as they do, while leaving out the COT market structure on the COMEX, is guaranteed to reduce one to the babbling idiot level. — Silver analyst Ted Butler: 05 June 2015 Another day—and more salami slicing in the all four precious metals, particularly gold and silver. There was decent volume associated with both metals, so it’s an absolute certainty that the Managed Money was puking longs and piling on the short side, while JPMorgan et al gobbled up everything on the opposite side of those trades for fun, profit and price management purposes. And it was a very profitable day for “da boyz” yesterday. Here are the 6-month charts for all four precious metals—and new lows were engineered in three of the four precious metals. The gold stocks opened down—and chopped more or less sideways for the remainder of the day, as the HUI closed down another 1.35 percent. It was more or less the same thing in the silver equities, although the trading day had more shape to it. The big drop because someone sold a boat load of shares in Peñoles right at the close, at least that’s what Nick said yesterday when I asked him. Because of that, Nick’s Silver Sentiment Index got hit for 2.26 percent. Without that share dump, the loss would have been about 0.5 percent. Without doubt, all eyes will be on the job numbers this morning The gold price chopped around, mostly lower, during the Far East trading session on their Thursday—and both the rally attempt in the Far East—and the one in early London trading, met with a resolute seller the moment that the price attempted to break above unchanged. JPMorgan et al, HFT algorithms in hand, did the dirty starting the moment that COMEX trading began—and by around 11:20 a.m. EDT, their work was done for the day, with another low for this move down. The gold price rallied quietly after that, before chopping sideways starting around 2:40 p.m. in electronic trading. The high and low tick were recorded as $1,186.60 and $1,172.40 in the August contract. The gold price closed in New York yesterday at $1,176.40 spot, down another $8.60 from Wednesday’s close. Net volume was very decent at 148,000 contracts. Here’s the 6-month U.S. Dollar chart as a reference. The dollar index finished the Wednesday trading session in New York at 95.37—and traded virtually ruler flat until about 1:30 p.m. Hong Kong time. At that juncture it rallied 20 basis points, hitting 95.56 at 8:30 a.m. BST in London trading. It fell of a cliff at 9 a.m. right on the button, hitting its 94.72 low about thirty five minutes later. Then at noon BST it appeared that ‘gentle hands’ showed up—and the dollar rallied to a handful of basis points above unchanged minutes before trading began in the equity markets in New York. It rallied higher from there in a rather choppy manner—and closed yesterday at 95.58—up 21 basis points from Wednesday. It’s obvious to me that the dollar would crash if given the opportunity to do so—and it’s equally as obvious that the powers-that-be are at hand to prevent that from happening.
People with HIV have been failed by the government’s new disability benefit, according to new research.The research by the National AIDS Trust (NAT) found that only three-fifths of people living with HIV were found eligible for the new personal independence payment (PIP) after being reassessed.NAT says its research has confirmed long-standing fears that people with HIV would not receive the support they needed under PIP, which is supposed to help cover people’s extra disability-related costs.Its report shows that only three-fifths (63 per cent) of the 1,000 people with HIV who were previously receiving disability living allowance (DLA) and had been reassessed for PIP were awarded the new benefit.This compares with 73 per cent of all DLA claimants who had been reassessed and were awarded PIP, according to the figures, published by the Department for Work and Pensions (DWP) last December.One charity that works with NAT, River House, described yesterday (Wednesday) how a 57-year-old man who was diagnosed last October with HIV and also had chronic obstructive pulmonary disease, had been awarded zero points after a PIP assessment in April.An appeal to the Department for Work and Pensions (DWP) – the so-called mandatory reconsideration stage – was refused in late June.By this time, his health had deteriorated even further and he was admitted to hospital, where he was diagnosed with untreatable lung cancer.He was due to receive DWP’s decision on a fresh PIP application this week, but died on Monday morning.Another River House service-user with HIV has described how he had to start using foodbanks after his PIP was suddenly stopped because he missed a renewal deadline by just two days after he was diagnosed with cancer.DWP refused to reconsider removing his PIP and he had to wait more than 16 weeks to be assessed again.He said: “From the moment that my PIP stopped, I lost the uplift in my ESA [employment and support allowance] that I received because I was now not receiving PIP.“While I waited to be assessed for PIP and again for ESA, I had to borrow small amounts of money from friends [and] organisations that support people living with HIV and I was a regular visitor to local food banks.”The NAT analysis also shows that people with HIV who had been claiming DLA were more likely (43 per cent) than the average DLA claimant (30 per cent) to see their level of support cut if they were awarded PIP after a reassessment.According to last December’s figures, only about 1,000 of the 7,920 people living with HIV who were claiming DLA at the start of the PIP rollout in 2013 – which itself was about 10 per cent of all those with HIV in the UK – had been reassessed.The charity says that not everyone living with HIV in the UK has benefitted equally from modern treatments – for example, long-term survivors and people diagnosed late – and some will have life-long health problems as a result of HIV. One study found that two-thirds of people living with HIV in the UK have at least one other condition, in addition to HIV, and 38 per cent have more than one additional condition.Deborah Gold, NAT’s chief executive, said: “The evidence so far is that PIP is not working for people living with HIV who need extra support.“The assessment is not fit for its stated purpose, to identify the disability-related barriers to participation and independence experienced by people living with HIV. “The tick-box eligibility criteria describe only the most basic aspects of existence, such as physical capacity to consume food and bathe, without any understanding of the social context of life with a serious long-term condition.”Among the charity’s many concerns about the assessment process are that it fails to accurately capture: the risk of isolation due to HIV-related anxiety; the need for support with nutrition; and the importance of adhering to HIV medication.Sarah Radcliffe, NAT’s director of policy and campaigns, said that the research – the first to be carried out into the impact of PIP on people with HIV – shows that the concerns raised when the abolition of working-age DLA was announced in 2010 were not baseless.She said the way the assessment was devised “means people living with HIV will not have their support needs identified – or where they are picked up, this will not necessarily translate to support”.And she said the social model “rhetoric” used by DWP when it introduced the new benefit – focussing on how social factors create barriers to participation for disabled people – “has not translated to reality for PIP”.Instead, she said, the PIP assessment “looks a lot like the work capability assessment’s notorious ‘tick box’ medical approach”.She added: “The descriptors used are proxies for a basic existence and not for barriers to participation or the extra costs associated with an active, independent life.“It is not too late to improve PIP for people living with HIV. The vast majority are yet to be reassessed. “It is time to look again at PIP, from scratch, and make sure it lives up to its stated goals of promoting participation and independence.”A DWP spokeswoman said in a statement: “We introduced PIP to replace the outdated DLA system – it takes a much wider look at the way someone’s health condition or disability impacts them on a daily basis and is tailored to suit each individual’s needs.“Decisions are made following consideration of all the information provided by the claimant, including supporting evidence from their GP or medical specialist.“Under PIP, 28 per cent of claimants are now receiving the highest rate of support, compared to 15 per cent under DLA, and anyone who disagrees with a PIP decision has the right to appeal.”But DWP figures from last December also showed that fewer than half (about 126,000) of the 254,000 people previously receiving the higher rate mobility component of DLA secured the same level of mobility support when reassessed for PIP.And unpublished DWP figures obtained by DNS in March showed nearly half of disabled people subject to “planned reviews” of their eligibility for PIP were having their existing award either cut or removed completely.NAT has produced free resources on PIP for people living with HIV and the services who support them
2019 Entrepreneur 360 List –shares Entrepreneur Staff Add to Queue The only list that measures privately-held company performance across multiple dimensions—not just revenue. Next Article Tesla But he’s been wrong before. Entrepreneur Staff Despite the name, Tesla’s Autopilot feature will not safely drive you home from work or anywhere else. Of course, that hasn’t stopped brazen Tesla owners from abusing the system (one was even allegedly drunk and asleep behind the wheel).But according to Tesla co-founder and CEO Elon Musk, true self-driving Tesla vehicles will be available next year.Related: The Daily Schedules of Jeff Bezos, Elon Musk, Oprah Winfrey and Other Famous Business Billionaires“I think we will be ‘feature complete’ on full self-driving this year, meaning the car will be able to find you in a parking lot, pick you up, take you all the way to your destination without an intervention this year,” Musk said during a podcast interview, as reported by Wired. “I am certain of that. That is not a question mark.”Of course, Musk has been off with his predictions in the past — just look at the whole production debacle he landed his company in after promising Tesla would manufacture 20,000 Model 3 cars a month by December of 2017. Yet still, Musk was at it again yesterday.Meant to say annualized production rate at end of 2019 probably around 500k, ie 10k cars/week. Deliveries for year still estimated to be about 400k.— Elon Musk (@elonmusk) February 20, 2019 Apply Now » 2 min read Image credit: Bloomberg | Getty Images February 20, 2019 Elon Musk Says True Self-Driving Teslas Could Be Ready in 2020
Sarah Jacobsson Purewal How to Clean Up an Online Reputation Add to Queue Free Webinar | July 31: Secrets to Running a Successful Family Business If you own a small or medium business, a good reputation — online and offline — is clearly key to your success. The stakes are also high for individuals, who can win or lose jobs based upon how they appear in Web search results.The Internet can overwhelm users with information, so anything negative — especially if it appears high in search results — can have a drastically harmful effect on your success and how people see you.Among U.S. recruiters, 70 percent have rejected candidates based on their online reputation — and yet only 7 percent of Americans believe that their online reputation can affect their job search, according to a 2010 study by Microsoft and Cross-Tab Market Research. A potential customer who searches for your business online is a lot like a recruiter, trying to find the best company for the job.Ignoring how you or your company appears in search results and on ratings Websites has arguably never been more perilous.One significant figure in the recently altered relationship between businesses and search engines is Vitaly Borker, owner of retail eyewear Website DecorMyEyes.com, who told the New York Times in November that his unconventional search engine optimization (SEO) strategy worked like a charm: Borker harassed customers, directing them to vent on the Internet. His Website thus climbed higher in Google’s search results, bolstered by the many links from established review Websites.Google immediately reworked its code and buried DecorMyEyes along with other businesses it deemed “bad.” Now that Google no longer rewards bad customer service with top spots in searches, it’s a good time to examine how your business can get more positive attention in legitimate ways.Should You Pay for Online Reputation Management?Deciding to take control of your online reputation is a daunting task, and you may be tempted just to hire someone to do it for you. Online reputation management companies abound on the Internet — claiming everything from 100 percent success rate (or your money back) to a “special technology” that reorders search results.Such companies may be worth looking into, but there is no magical way to erase content from the Internet. Once something is uploaded to the Web, it’s impossible for you or a third party to remove it without help from the administrator of the Website where it appears.It’s even harder to remove content from search engines (like Google) that cache their results and enable surfers, with the click of the Cached link, to view content that has been “removed.” In addition, the Internet Archive’s Wayback Machine stores records of Websites dating back to the 1990s.Organizations such as ReputationDefender, RemoveYourName, and Integrity Defenders offer business packages to help you take on your online reputation. Essentially, however, these services focus on two tasks: requesting that negative information about you or your company be taken down, and helping you create new content to displace the negative content.ReputationDefender, which is perhaps the best-known reputation-oriented service, charges between $3000 and $10,000 to monitor your reputation. RemoveYourName and Integrity Defenders are a bit cheaper; their packages start at $3000 and $630, respectively. Often the quoted prices are just a starting point. ReputationDefender charges extra, for example, for helping you get rid of unsavory remarks that they uncover.Here are some key points to remember if you decide to hire an online reputation management company:Weigh any negative reviews of the company more heavily than you normally would. Remember, these companies are in the business of defending and rehabilitating reputations; if 10 “bad” reviews of their own service get through, imagine how many others they may have buried.No company has the magical power to automatically remove negative reviews from the Internet.Consider the benefits of a service that charges monthly versus a flat-fee service. Monthly services, such as BrandsEye, will constantly monitor your reputation. Flat-fee services, such as RemoveYourName, will spend as much time as it takes to get results. If you’re looking to remove specific negative reviews, a flat-fee service might be best for you; but if you just want someone to monitor your reputation, a monthly service makes more sense.It’s entirely possible that a reputation-monitoring service won’t be able to help you, or that the service’s efforts may backfire. In the case of Ronnie Segev, ReputationDefender and a blog called The Consumerist ended up in a spitting match after ReputationDefender requested that an article about Segev be removed.If you don’t have room in your budget for professional reputation management — or if you’ve decided that the service doesn’t justify the price — you can take on tracking and managing your online reputation by yourself.Step 1: Track Your Online PresencePerform a search for your company name in a general search engine, such as Google or Bing. Be sure to search not only for your company’s name, but also for related keywords, possible misspellings, and phrases (utilizing quotation marks). Note any negative reviews and where your company’s Website appears in relation to them (higher or lower). Cross-check your search on other search engines. For tips on effective ways to perform more-detailed searches, see “28 Time-Saving Tricks for Google, Facebook, and More.”Run site-specific searches on relevant Websites, including social media Websites such as Facebook and Twitter, review Websites like Yelp and Kudzu, and consumer advocacy sites such as GetSatisfaction and Ripoff Report. To perform a site-specific search of reviews of cupcake makers on Yelp, for example, type the following into Google: cupcake site:yelp.comSearch for individuals if you want to track the information available about you or your colleagues on people search engines such as Spokeo. Though most of these sites simply grab information that’s publicly available from other sources, you can try contacting them directly to request that they not present all the data to the public.Sign up for alerts from search engines. Google Alerts allows you to track search terms by type. The service will send any new mentions of your search term to your inbox daily, weekly, or in real time.Consider using BrandsEye or a similar service. This is one part of the process where paying for a service can definitely be useful. BrandsEye, which costs about $100 per month, not only tracks your online presence, but analyzes it, too. BrandsEye weighs each mention of your company as coming from an important or unimportant source and gauges how much effect each mention has on your overall reputation (similar to the way the Google search algorithm supposedly works).Step 2: Address the IssuesRead the reviews, both negative and positive. People usually spend more time reviewing services they feel strongly about, whether that feeling is love or hate. You can thus use negative online reviews constructively, especially if reviewers bring up legitimate complaints.Contact Websites if you encounter any false or unnecessarily vindictive reviews, and request that they be removed.Respond to customer complaints by apologizing and offering your side of the story. Then if someone later sees the negative comment about your company, they’ll also see that you’re committed to fixing and fostering good relationships with your customers. No matter how tempting it is, never trade insults with the customer — it’s harder for potential customers to identify with you than with a fellow consumer.Step 3: Connect and Create ContentConnect with your customers via social networking Websites. It’s not enough to have a Facebook page or a Twitter account that you post dry, business-related updates to — you have to engage your customers and help them get to know you, your business, and your brand. Content should be interesting — now is not the time to pitch your business or products — and try to encourage feedback from your followers.Create original content for the search engines, to displace any negative content that is currently popping up. This may take the form of anything from blog posts to informative articles to contests.Never “astroturf” by posting fake reviews, no matter how Web-savvy you are. If you’re found out, you’ll lose the respect of your customers, and you could also face legal trouble.Online reputation management might seem like a full-time job, but that’s not necessarily the case. If you take the steps to gauge the general tone of your brand’s online presence and discover that you’re doing a pretty good job, retaining a professional reputation defense company to obliterate one or two bad reviews makes little sense.If, on the other hand, your brand has a less-than-stellar reputation on the Internet, be aware that there is no one-step route to a rehabilitated rep; slow and steady relationship building is the most effective way to gain the reputation you desire. In most instances, a small business’s marketing teams should be able to handle online reputation management, since much of the task involves basic social networking and Website upkeep, along with reaching out to the clientele.Unfortunately, bad things have a way of snowballing — or “going viral” — on the Internet, so it’s possible that a bad hit to your reputation can become a big deal if you handle it poorly or fail to handle it at all. In these situations, having someone — whether it be a professional company or a full-time staff member — dedicated to protecting your reputation can be very helpful. If your online reputation is getting too hot to handle, for whatever reason, bringing in professional help should remove some of the stress. But no matter how professional a company or individual dedicated to online reputation management may be, ultimately they can’t do anything that you couldn’t do yourself with enough time and persistence. 9 min read January 14, 2011 Marketing Controlling how you appear in search results and on social networking sites doesn’t have to be hard. Brought to you by PCWorld Learn how to successfully navigate family business dynamics and build businesses that excel. Next Article –shares Register Now »
Learn how to successfully navigate family business dynamics and build businesses that excel. Eddie Antar died this weekend at age 68. Register Now » Jason Fell News and Trends Free Webinar | July 31: Secrets to Running a Successful Family Business Director of the Entrepreneur Partner Studio Eddie Antar (R) once known as Crazy Eddie Next Article September 12, 2016 Eddie Antar was an entrepreneur who realized the highs of business success as well as the lows of fraud and running from authorities. You might not recognize his name, but if you were alive in the late 1970s and 1980s, you’d be hard pressed not to know his business: he was the founder of the Crazy Eddie discount electronics store chain.From his quirky TV and radio commercials, how could you forget that his prices were totally “inasaaaaaane!”Antar died on Saturday. He was 68.Born in 1947, Antar opened his first Crazy Eddie electronics store when he was in his early 20s, in Brooklyn, N.Y. With the help of his popular commercials – which aired for nearly 15 years and starred radio personality Jerry Carroll – the business grew into a small empire of stores up and down the East Coast. VCRs, video games and camcorders (remember those?) were hot sellers at the time.But Antar’s “success” wouldn’t last forever. Here’s a quick look at 11 moments during his rise and fascinatingly bizarre fall:Antar opened his first Crazy Eddie electronics store in 1969 on Kings Highway in Brooklyn.The term “crazy” came from Antar’s wild sales style. Apparently, he’d accept customers’ shoes as deposits on items like TVs or stereos.His first commercial aired in 1975. Each one ended with the phrase, “’Crazy Eddie, his prices are insaaaaaane!” He continued to open new locations in the New York metro area.Riding the brand’s popularity (those ads were memorable), Antar took the company public in 1984.At its height, the company had more than 40 locations from Boston to Philadelphia, and was generating as much as $350 million in revenue a year.By 1987, stockholders discovered that $45 million in merchandise was missing. His business and accounting practices were called into question and the stockholders staged a takeover of the company. After all, how could he have such insanely low prices?Federal prosecutors eventually charged Antar and his family of skimming cash and manipulating the company’s stock.In 1989, Crazy Eddie filed for bankruptcy and its final store closed.The following year, Antar fled the country and was later found living in Israel. He was extradited and served seven years in U.S. prison.Antar’s cousin, Sam, who was the company’s CFO, pleaded guilty to fraud and later served as a consultant to governmental agencies that were investigating accounting fraud.In 2001, a newly freed Antar attempted to bring Crazy Eddie’s back, selling electronics online. Despite the cheesy ads, there wasn’t enough steam in the brand for a second go and the company failed. Add to Queue –shares 11 Insaaaane Things You Didn’t Know About the Founder of Crazy Eddie 3 min read Entrepreneur Staff Image credit: Sven Nackstrand/AFP | Getty Images
While audio advertising has been relatively consistent for the better part of 50 years, it’s now going through a massive transformation. It’s no longer as simple as putting out a big (and often impersonal) ad campaign in an effort to reach the people you’re trying to reach. Today, it’s all about reaching the right people via the right platform at precisely the right moment while giving them a much more targeted and personalized experience.Over the past 15 years, we’ve watched the industry progress from “radio” to “audio” and the strengths of the medium develop from reliable to innovative. In the spirit of reflection, it’s interesting to examine just how much audio advertising has evolved.These are some of the biggest changes we’ve seen:Opportunities GaloreIt’s hard to imagine, but before 2000, the mainstays of today’s audio landscape barely existed– satellite radio, streaming and podcasts were just starting to emerge. Of course, these channels have exploded in popularity and continue to evolve rapidly, opening up a dearth of opportunities for brands to connect with new audiences. Unlike TV and digital ads, audio ads don’t have to compete with other ads for eyeballs or work within the space confines of a screen.Today’s listeners are much more tuned in and engaged with what they’re listening to, providing greater opportunities for advertisers to reach them.Podcast listeners, for example, have been shown to be so invested in their favorite shows that they actively listen to ads contained within the episode. And, if a podcast host endorses a particular product, even better as listeners tend to be more open to the product. Even with the availability of ad-free streaming services, millions of listeners opt to listen to the ad-supported versions of Spotify and Pandora, again giving brands the chance to share their products and services with a more engaged audience.Content ExplosionNaturally, the rise of these opportunities goes hand in hand with the explosion of audio content. While years ago talk radio dominated the audiowaves, podcasts are taking center stage. There are over 600,000+ active podcasts shows catering to just about every topic or interest imaginable.With podcasts, listeners hear exactly what they want to hear, exactly when they want to hear it, giving advertisers the ability to reach exactly who they want to reach when they want to reach them.One of the biggest advantages for an advertiser of endorsed audio is the “host trust factor.”When your favorite host or influencer tells you how much they love a product or service, loyal listeners activate and buy that product or service.More FragmentationOf course, with more opportunities and content comes more fragmentation. From 1922 when the first radio ad ran to even 10 years ago, AM/FM radio was a straight shot for an advertiser looking to connect with Americans en masse.But with so many opportunities to reach target audiences today, how do advertisers decide where to invest their dollars? Yes, audiences are much more engaged, but what about search and discovery? With 120,000 podcasts launched in the last year alone how do advertisers find the shows or identify the hosts or influencers that will best align with their products?One big way advertisers are combating these challenges is through AI. AI technology (like our aiWARE platform) can surface tons of data to find what’s most meaningful to brands, discover new content, find the right podcast influencer and help guide brands to making smart, cost-effective decisions around their ad spend.What’s On The Horizon?As we usher in 2019, we look forward to watching the audio advertising landscape continue to evolve. We expect that audio content, especially podcasts and voice-enabled devices, will become more unique and personalized.We also expect podcasts will continue to become mainstream and even get closer to finding the listener (instead of the listener looking for the podcast).While these opportunities and content expand, we believe that AI will continue to guide audio advertisers on their quest to delivering a more meaningful and personalized customer experience.If we’ve learned anything in the last few years it’s that the audio space is full of surprises. As the industry continues to innovate, advertisers will need to keep pace and challenge themselves to take full advantage of the opportunities that await. Thirty years in the media business and involved in over $1 billion of ad campaigns.One thing is certain, AUDIO IS BACK! The Evolution of Audio Advertising and What’s Next in 2020 Zeus PeleusesJune 3, 2019, 8:23 pmJune 3, 2019 AIAudio AdvertisingAudio Contentcontent marketingpodcastsprogrammatic advertisingRadio AdvertisingTV adsVeritone One Previous ArticlePernix Launches Attribution Application Solution to Brings Full Transparency to Performance Marketing ProgramsNext ArticleUpland Software Acquires Kapost, Raises Guidance
Reviewed by Kate Anderton, B.Sc. (Editor)Feb 1 2019This software analyzes patients’ computed tomography (CT) results within 20 seconds and provides an image in which the pathology is clearly markedResearches from Peter the Great St.Petersburg Polytechnic University (SPbPU), Russian Academic Excellence Initiative participant, in collaboration with the radiologists from St.Petersburg Clinical Research for Specialized Types of Medical Care (Oncological) have developed an intelligent software system for lung cancer diagnostics. This software can be installed on any computer. It analyzes patients’ computed tomography (CT) results within 20 seconds and provides an image in which the pathology is clearly marked. Researchers have named the system Doctor AIzimov (AI for Artificial Intelligence) in honor of the science-fiction writer Isaac Asimov, who developed three famous laws of robotics.At the end of 2018, the first tests of this intelligent system were carried out. The system analyzed anonymized CT images of 60 patients at the Oncological Center. According to the radiologists, the tests were successful, as the system has found focal nodules in lungs of small sizes (2 mm).”Initially, we set up an algorithm to search for nodules starting from 6 millimeters, because radiologists themselves start the treatment of tumors of this size. But the system is so smart that it was able to find nodules of even smaller size”, said the project lead Lev Utkin, the head of the SPbPU Research Laboratory of Neural Network Technologies and Artificial Intelligence.Research team includes the staff of the University (Lev Utkin, Mikhail Ryabinin, and Alexei Lukashin), experts from the St. Petersburg Oncological Center (the head of the Radiology Department Anna Meldo and a radiologist Ivan Prokhorov). The project was supported by the Russian Science Foundation.A new proposed and developed approach to the lung cancer classification using the chord method has been patented within only 3 months. The method of chords uses segmented CT images: points are randomly drawn on the surface of a nodule, after that the points are connected by lines (chords). The length histogram of the chords reflects the shape and structure of the tumor. Although the system examines every nodule from the inside, its external surroundings are also very important. To learn more about the tumor, it is placed in a cube, and perpendiculars are drawn from its edges to the surface of the nodule.Related StoriesNew protein target for deadly ovarian cancerLiving with advanced breast cancerStudy reveals link between inflammatory diet and colorectal cancer riskThus, instead of classifying a graphically complex and heavy images of the CT (the size of every CT image is approximately 1 GB), the nodule is represented in the form of compact and simple histograms, which are then analyzed by the Doctor AIzimov system.The scientists have also trained the system to distinguish malignant and benign tumors. “Many different objects may be detected on the CT images, so the main task was to train the system to recognize what each of the objects represents. Using the clinical and radiological classification, we are trying to train the system not only to detect tumors, but also to distinguish other diseases similar to cancer,” comments Anna Meldo, the head of the Radiology Department of the St. Petersburg Clinical Research Center for Specialized Types of Medical Care (Oncological). The system was trained by analyzing 1000 CT images from LUNA 16 and LIDC datasets. Russian researchers have also collected their own dataset named LIRA – Lung Intelligence Resource Annotated. Currently, the dataset holds CT images of about 250 patients. The scientists are planning to increase the number of images by four times by the mid-2019.With each new CT image, the system self-improves. To speed up the learning and testing processes, the researchers use capacities of the supercomputer center “Polytechnic”. In the future, a patient’s CT images will be transferred to the supercomputer using the Internet. This approach allows to reduce the diagnostic testing time per patient from 20 till 2 seconds. After that a radiologist will receive the marked image instead of the large CT image. It will significantly reduce the time needed for the analysis and diagnostics.The open testing of the intelligent system will be carried out at the beginning of 2019. The system will be at first used at the St. Petersburg Clinical Research Center for Specialized Types of Medical Care (Oncological). In the future, the project will be extended and more medical institutions will be involved into the intelligent CT image processing. The system will be adapted to analyze the results of the ultrasound and X-ray medical investigation of other organs. All data will be processed by the supercomputer, and the results issued by the system will be sent to doctors for them to make a decision about the treatment. Source:https://english.spbstu.ru/
Source:https://www.mailman.columbia.edu/ Reviewed by Kate Anderton, B.Sc. (Editor)Apr 25 2019Awareness and diagnoses of hypertension and diabetes in China has been limited, resulting in compromised treatment, and increased screening did not lead to significant improvements, according to a new study at Columbia University Mailman School of Public Health. Findings are online in the journal BMC Public Health.Until now, there was little information on how individuals with hypertension or diabetes in China first became aware of their conditions and what factors may have contributed to changes in awareness over time.”It does not seem that the screening activities implemented by a national health survey improved awareness and management of these conditions. The persistent limited awareness of diabetes and hypertension remains a major public health concern,” said L.H. Lumey, MD, professor of Epidemiology.Using data from the China Health and Retirement Longitudinal Study (CHARLS), researchers measured the impact of a screening program for people aged 45 years and older between 2011 and 2015. After 2011, study participants were re-interviewed every two years to monitor any changes over time in their health, economic, or social conditions. Physical examinations were repeated in 2013 and 2015, and participants were asked again if they had ever been diagnosed with hypertension, or diabetes. Over 80 percent of participants interviewed in 2011 continued to participate in 2015.Of the more than 11,000 people screened in 2011, 49 percent were identified with hypertension and 18 percent with diabetes by medical examinations. Over 80 percent of the middle-aged and elderly Chinese diagnosed with hypertension and/or diabetes in 2011 reported in 2015 that they were unaware of having the disease(s). Aware hypertension patients were more likely to be older women, live in urban areas, and have higher BMIs.Hypertension was defined as diastolic blood pressure of 90 mmHg or higher; a systolic blood pressure of 140?mmHg or higher; or both; or as currently using an anti-hypertensive medication. Diabetes was defined as a fasting plasma glucose level of 126?mg/dL or higher; an HbA1c concentration of 6.5 mg/dL or higher; or a self-report of doctor diagnosed diabetes.Related StoriesObese patients with Type 1 diabetes could safely receive robotic pancreas transplantDiet and physical exercise do not reduce risk of gestational diabetesSome people treated for type 1 diabetes may have monogenic diabetes, study findsThere was some improvement in disease awareness between 2011 and 2015, mostly attributed to a medical examination initiated by the study participants themselves (over 75 percent), by their work unit or community (12-15 percent), but rarely (less than 3 percent) by the CHARLS examination. “One possible explanation is that the screening in the health survey was seen simply as an isolated process and not as a tool for follow-up, treatment, or referral,” noted Lumey.Several reasons could explain the limited increase in reported disease awareness in 2015, according to the researchers. Some participants may not have received the physical examination and blood test results from the 2011 survey; they may have not understood the results; or, they may have forgotten the results. “They also may have been unwilling to recognize that they had been diagnosed with diabetes or hypertension or failed to take appropriate measures for disease management,” said Lumey. “This will need further study.””While we observed an increase in hypertension and diabetes awareness over time in the CHARLS survey, our results suggest a ‘failure to act on the findings’, and raise important questions about the effective communication of screening results not only in CHARLS but also in other health surveys,” noted Chihua Li of Zhengzhou Central Hospital in China.”Perhaps individuals were expected to take actions by themselves after receiving the screening results,” said Lumey. “But our findings show it is important that increased efforts are made to make sure that participants understand the medical examination results and are motivated to access the appropriate health services where needed. Providing systematic feedback of screening results to survey participants and the monitoring of disease awareness over time will be essential to improve disease recognition and facilitate optimal management.”
Panel formed to submit a detailed report in one month Published on Telangana Despite the Central Government remaining silent on the proposal to set up an integrated steel plant in Bayyaram, the Telangana Government has resolved to take up the issue more vigorously.The State Government has repeatedly approached the Centre for the past four years for setting up the plant. Despite giving an assurance of bearing 50 per cent of the expenditure, there is no positive response, said the Minister for IT & Industries, K T Rama Rao. The Government has constituted a committee to study and submit a detailed report on Bayyaram steel plant in one month. It includes officials from Energy, Singareni, Mines and Geology & TSMDC Departments. The committee will study the process of establishment of a steel plant and availability of land, water and iron ore resources and road connectivity. As per AP State Reorganisation Act 2014, Telangana has been assured a steel plant at Bayyaram. “Though there are a lot of possibilities for setting up of a steel plant at Bayyaram, the Central Government is not responding positively since four years,” Rama Rao stated as per an official release. The Telangana Government has been pursuing the issue of setting up of the steel plant with the Union Government. The Minister reiterated that the State Government would continue its efforts to get the steel plant established at Bayyaram at any cost. “The Telangana Government is committed to Bayyaram steel plant with or without the support of Government of India,” the Minister contended. The steel plant at Bayyaram is expected to create a lot of direct and in indirect employment opportunities in the State. COMMENTS Telangana Minister for IT & Industries, K T Rama Rao. – The Hindu SHARE SHARE EMAIL SHARE June 18, 2018 iron and steel COMMENT